Tertiary lymphoid structures (TLSs) are defined as lymphoid aggregates formed in non-
hematopoietic organs under pathological conditions. Similar to secondary lymphoid organs …

Malignant mesothelioma (MM) is a rare and aggressive neoplasm, usually associated with a
poor prognosis (5 years survival rate< 10%). For unresectable disease, platinum and …

Immunotherapies have shown great promise in pleural mesothelioma (PM), yet most
patients still do not achieve significant clinical response, highlighting the importance of …

Simple Summary Malignant pleural mesothelioma (MPM) is an aggressive cancer linked to
asbestos exposure with an extremely poor outcome. Despite the recent approval of immune …

Pleural mesothelioma (PM) is an aggressive and rare disease, characterized by a very poor
prognosis. For almost two decades, the world standard treatment regimen for unresectable …

Abstract Purpose of Review In this article, we provide a comprehensive analysis of recent
progress in the genetic characterisation of pleural mesothelioma, and the translation of …

Asbestos (all forms, including chrysotile, crocidolite, amosite, tremolite, actinolite, and
anthophyllite) is carcinogenic to humans and causally associated with mesothelioma and …

Although clinical antitumor activity of Tumor Treating Fields (TTFields) has been reported in
malignant pleural mesothelioma (MPM) patients, the mechanisms behind the different …

Simple Summary The role of tertiary lymphoid structures (TLSs) in cancer has been
extensively studied, including predicting good prognosis and immunotherapy efficacy …

Simple Summary Advances in malignant pleural mesothelioma research have led to the
approval of first-line immunotherapies and the development of numerous trials of new first …